PMID: 7033147Sep 15, 1981Paper

Glycosphingolipids of K562 cells: a chemical and immunological analysis

International Journal of Cancer. Journal International Du Cancer
A SuzukiD M Marcus

Abstract

The K562 cell line, which was established from a patient with chronic myeloid leukemia in blast crisis, was thought to be myeloid, but recent data indicate that it is an undifferentiated erythroid cell line. We have found that the glycosphingolipid content of these cells differs considerably from that of mature erythrocytes. Globotetraosylceramide, the most abundant glycolipid of mature red cells, was not detected in K562 cells, and neither was globotriaosylceramide. The predominant neutral glycolipids of K562 cells are monohexaosylceramides, which are a mixture of glucosyl- and galactosylceramides, and lactotriaosyl- and lactoneotetraosylceramides were also detected. Secondly, gangliosides which contain N-acetylgalactosamine were much more abundant than those containing N-acetylglucosamine in K562 cells, in contrast to erythrocytes. The most abundant ganglioside of K562 cells, GM2, is present in trace quantities in erythrocytes. A third major difference between these two cells lies in their relative proportions of neutral glycolipids and gangliosides. The molar ratio of neutral glycolipids/gangliosides is approximately 15:1 in erythrocytes and 1:1 in K562 cells. These striking differences between K562 cells and mature erythroc...Continue Reading

References

Nov 29, 1977·Biochemistry·K E Stein, D M Marcus
Feb 1, 1979·International Journal of Cancer. Journal International Du Cancer·L C AnderssonC G Gahmberg
Sep 1, 1979·Clinical Immunology and Immunopathology·G K Schwarting, D M Marcus
Dec 15, 1979·International Journal of Cancer. Journal International Du Cancer·L C AnderssonP Vuopio
Sep 1, 1976·Proceedings of the National Academy of Sciences of the United States of America·D M MarcusS K Kundu
Oct 1, 1973·Journal of Neurochemistry·R W LedeenL F Eng
Jan 1, 1980·Journal of Neurochemistry·S K KunduR W Veh
Feb 1, 1980·Scandinavian Journal of Haematology·L C AnderssonC G Gahmberg
Jan 1, 1981·Immunological Communications·R A KarolD M Marcus
Dec 1, 1980·Journal of Immunogenetics·S K KunduD M Marcus
Nov 1, 1980·Revue française de transfusion et immuno-hématologie·R A KarolD M Marcus

❮ Previous
Next ❯

Citations

May 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·R KannagiS Hakomori
Jun 14, 2013·Proceedings of the Japan Academy. Series B, Physical and Biological Sciences·Donald M Marcus
Jun 18, 2014·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Un-Ho JinCheorl-Ho Kim
May 1, 1986·British Journal of Haematology·A E von dem BorneP A Tetteroo
Nov 19, 1985·Biochemistry·J BuehlerB A Macher
Jul 15, 1983·International Journal of Cancer. Journal International Du Cancer·J A WerkmeisterJ C Roder
Jul 15, 1987·International Journal of Cancer. Journal International Du Cancer·I AndoR F Irie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.